Ciclopirox Nail Lacquer DTC Ads Should Be Avoided - FDA Advisory Cmte.
Executive Summary
Direct-to-consumer advertising of Hoechst Marion Roussel's ciclopirox nail lacquer treatment for onychomycosis should be avoided because of the narrow population for which the drug is effective, FDA's Dermatologic & Ophthalmic Drugs Advisory Committee said Nov. 4.
You may also be interested in...
Penlac Must Be Part Of Comprehensive Management Program, Labeling Says
Aventis' Penlac nail lacquer must be used as part of a comprehensive management program in the treatment of fingernail and toenail fungus, labeling states.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011